Corvus Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Si prevede che Corvus Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 12.1% e 78.7% all'anno, mentre si prevede che l'EPS crescerà del 20.5% all'anno.

Informazioni chiave

12.1%

Tasso di crescita degli utili

20.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.6%
Tasso di crescita dei ricavi	78.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	19 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:CRVS - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	3	-50	-9	N/A	4
12/31/2025	1	-35	3	N/A	4
12/31/2024	N/A	-58	-7	N/A	4
9/30/2024	N/A	-57	-22	-22	N/A
6/30/2024	N/A	-23	-21	-21	N/A
3/31/2024	N/A	-25	-21	-21	N/A
12/31/2023	N/A	-27	-24	-24	N/A
9/30/2023	N/A	-30	-26	-26	N/A
6/30/2023	N/A	-39	-28	-28	N/A
3/31/2023	N/A	-41	-29	-29	N/A
12/31/2022	N/A	-41	-27	-27	N/A
9/30/2022	N/A	-41	-27	-26	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-40	-34	-34	N/A
12/31/2021	N/A	-43	-37	-37	N/A
9/30/2021	N/A	-7	-38	-38	N/A
6/30/2021	N/A	-6	-37	-37	N/A
3/31/2021	N/A	-5	-34	-34	N/A
12/31/2020	N/A	-6	-35	-35	N/A
9/30/2020	N/A	-44	-35	-35	N/A
6/30/2020	N/A	-46	-38	-38	N/A
3/31/2020	N/A	-48	-38	-38	N/A
12/31/2019	N/A	-47	-37	-37	N/A
9/30/2019	N/A	-46	-37	-37	N/A
6/30/2019	N/A	-46	-38	-37	N/A
3/31/2019	N/A	-44	-39	-39	N/A
12/31/2018	N/A	-47	-41	-41	N/A
9/30/2018	N/A	-48	-44	-44	N/A
6/30/2018	N/A	-51	N/A	-44	N/A
3/31/2018	N/A	-54	N/A	-45	N/A
12/31/2017	N/A	-56	N/A	-46	N/A
9/30/2017	N/A	-55	N/A	-45	N/A
6/30/2017	N/A	-52	N/A	-41	N/A
3/31/2017	N/A	-46	N/A	-35	N/A
12/31/2016	N/A	-36	N/A	-28	N/A
9/30/2016	N/A	-31	N/A	-22	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-36	N/A	-15	N/A
12/31/2015	N/A	-31	N/A	-11	N/A
9/30/2015	N/A	-25	N/A	-7	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CRVS rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CRVS rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CRVS rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CRVS ( 78.7% all'anno) crescerà più rapidamente del mercato US ( 9.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CRVS ( 78.7% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CRVS è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/22 02:10
Prezzo dell'azione a fine giornata	2024/12/20 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Corvus Pharmaceuticals, Inc. è coperta da 12 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Dane Leone	BTIG
Li Wang Watsek	Cantor Fitzgerald & Co.
Vamil Divan	Credit Suisse

Corvus Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 9.1% to US$7.50

Price target decreased to US$2.50

Price target increased to US$6.38

Price target increased to US$6.30

Price target increased to US$7.38

Price target decreased to US$6.50

Recent updates

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals: The Market Likes The Story

Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Corvus Pharmaceuticals, Inc Grants FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Price target increased by 9.1% to US$7.50

Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

New minor risk - Market cap size

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

New major risk - Revenue and earnings growth

Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors

Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

New major risk - Financial position

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Price target decreased to US$2.50

Insufficient new directors

Corvus Pharmaceuticals, Inc. to Present Updated CPI-818 (ITK Inhibitor) Data At the American Society of Hematology Annual Meeting & Exposition

Corvus Pharmaceuticals Receives Written Notice from the Staff of the Listing Qualifications Department of Nasdaq

Corvus Pharmaceuticals, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Corvus Pharmaceuticals, Inc. Provides Business and Clinical Update

Corvus Pharmaceuticals, Inc. Appoints Dr. James Rosenbaum as Senior Vice President of Research

Price target increased to US$6.38

Insufficient new directors

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Chief Financial Officer recently bought US$77k worth of stock

Corvus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Insufficient new directors

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as A Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Price target increased to US$6.30

Corvus Pharmaceuticals Provides Updates on Mupadolimab

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Independent Director Steve Krognes has left the company

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

Price target increased to US$7.38

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

Co-Founder recently bought US$100k worth of stock

Price target decreased to US$6.50

Co-Founder recently bought US$350k worth of stock